Synektik Sa · GPW:SNT
Synektik Sa — Q3 FY2024 Earnings Presentation
23 slides from Synektik Sa's earnings presentation, August 2025
Slide 1: Investor Presentation Q3 FY 2024: Financial results
SYNEKTIK SA Investor Presentation Q3 FY 2024: Financial results August 2025 Q3 FY 2024 Financial results | Investor presentation 1
Slide 2: Synektik in snapshot
Synektik in snapshot WIG, mWIG40, Indexes WIGTECH, WIG-Poland ISIN PLSNKTK0001 428m 123m Number of shares 8 529 129 PLN PLN Capitalisation(1) PLN 1.86bn REVENUE FROM SALES, EBITDA FROM CONTINUING Enterprise value(2) PLN 1.87bn Q1-Q3 FY2024 OPERATIONS Q1-Q3 FY2024 P/E(3) 17.1 EV/EBITDA(4) 12.0 Compan
Slide 3: Highlights of Q3 FY2024
Highlights of Q3 FY2024 Sales of equipment and IT solutions – growing profits, exciting business perspectives PLN 139.4 million in revenue (excluding intra-group transactions) in Q3 FY 2024, including PLN 82.1 million in recurring revenue (69% YoY growth); PLN 42.8 million EBITDA, EBITDA margin of
Slide 4: Financial performance in Q3 FY2024
Financial performance in Q3 FY2024 Consolidated revenue (PLN million) 22% increase in total revenue from sales of equipment, IT solutions and Q3 FY2024 154.2 services (excluding intra-group transactions) +24% Q3 FY2023 124.0 51% increase in revenue of the radiopharmaceuticals segment, excluding
Slide 5: Financial performance in Q1-Q3 FY2024
Financial performance in Q1-Q3 FY2024 PLN 444.7 million in revenue from the sale of equipment, IT solutions and Consolidated revenue (PLN million) services, compared to PLN 450.6 million in revenue in Q1-Q3 FY 2023, 66% Q1-Q3 482.1 FY2024 increase in recurring revenue, to PLN 227.6 million 0% Q1-Q
Slide 6: Group's adjusted EBITDA in FY 2021-2024
Group’s adjusted* EBITDA in FY 2021-2024 Adjusted* EBITDA EBITDA growth driven by: (PLNm) 52.7 50.5 Growing scale of recurring sales in both 41.6 segments, characterized by attractive 29.8 30.4 31.7 31.7 33.8 margins 24.9 24.9 13.3 Increase in sales of equipment used in 10.9 5.5 6.2 7.1 therapy
Slide 7: Group's recurring sales in FY 2021-2024
Group’s recurring sales in FY 2021-2024 Recurring revenue for past 4 quarters Dynamic growth of recurring revenue (PLNm) 35.0 Drivers: Dynamically increasing demand for consumable 33.2 parts and accessories for therapy equipment sold 31.9 by the Synektik Group Revenue from sales of radiopharmaceut
Slide 8: Selected financial data
Selected financial data PLN 000s Q3 FY 2024 Q3 FY 2023 Q1-Q3 FY 2024 Q1-Q3 FY 2023 Sales revenue 154 238 123 979 482 060 482 978 Cash surplus over financial liabilities amounting to EBIT* 36 435 27 806 107 496 97 568 nearly PLN 16 million as of June 30, 2025 EBIT margin* 23.6% 22.4% 22.3% 20.2% EB
Slide 9: Medical equipment and IT solutions
SYNEKTIK SA Medical equipment and IT solutions Q3 FY 2024 Financial results | Investor presentation 9
Slide 10: Medical equipment and IT solutions: key information
Medical equipment and IT solutions Key information Synektik is a leading provider of medical equipment and IT solutions used in radiology, oncology, cardiology and neurology Core areas: Sale of medical equipment from several leading manufacturers, used in radiology, therapy and nuclear medicine
Slide 11: Medical: Financial results
Medical equipment and IT solutions Financial results (PLN million) Growing business profitabiity 450.6 443.7 22% increase in sales (year-over-year) in Q3 FY 2024, up to PLN 139.4 million 35% increase in EBITDA in Q3 FY 2024, up to PLN 42.8 million 104.5 125.6 PLN 444.7 million in revenue in Q1
Slide 12: Medical: Promising prospects for the coming quarters
Medical equipment and IT solutions Promising prospects for the coming quarters Sales of medical equipment, orders for implementation and active offers (in PLN million) Secured orders worth PLN 246 million in Q1-Q3 FY 2024 The value of active offers as of the end of June 2025 is PLN 137 million,
Slide 13: Commercialization of da Vinci system
Medical equipment and IT solutions Commercialization of da Vinci system Da Vinci assisted surgical procedures in Poland, Czech Republic and 9000 Slovakia (number) 96 8000 Approximately 5.1 k surgeries with the assistance of da Vinci in Q3 FY 2024 in Poland (up 57% y/y), 17.6 k in the last 4 quarte
Slide 14: Da Vinci systems serviced by Synektik
Medical equipment and IT solutions Gdynia Da Vinci serviced by GK Synektik Słupsk Gdańsk Olsztyn 105 69 Szczecin Białystok Bydgoszcz Toruń Wieliszew Biała Podlaska Grodzisk Da Vinci systems serviced da Vinci systems Gorzów Wlkp. Maz. by GK Synektik in Poland* Poznań Warszawa Siedlce Zielona Góra Les
Slide 15: Hospital pharmacy automation
Medical equipment and IT solutions BD Rowa Vmax APOTECAchemo Hospital pharmacy automation Comprehensive offer of GK Synektik for hospital pharmacies ▪ APOTECAchemo – robotic system for the automated preparation of intravenous chemotherapeutic compounds ▪ BD Rowa robotic pharmacy systems automating t
Slide 16: Hospital pharmacy – Sales prospects PLN 1,9 bn
Medical equipment and IT solutions Hospital pharmacy– Sales prospects PLN 1,9 bn The hospital pharmacy sector is ready for accelerated technological transformation based on automation: Market potential for the modernization of hospital pharmacies in the field of drug ▪ Increased availability of fund
Slide 17: Radiopharmaceuticals
SYNEKTIK SA Radiopharmaceuticals Q3 FY 2024 Financial results | Investor presentation 17
Slide 18: Radiopharmaceuticals: Key information
Radiopharmaceuticals Key information Synektik is the largest producer and supplier of PET/CT radiopharmaceuticals in Poland 50+ Number of 3 Production sites together employees with R&D Centre Major producer of special radiopharmaceuticals Location of cyclotrons for the production of radiopharmac
Slide 19: Radiopharmaceuticals: Financial results
Radiopharmaceuticals Financial results (PLN million) Growing revenues, strong margins 38.3 32.3 51% increase in sales (year-over-year) in Q3 FY 2024, up to PLN 14.8 million 12.0 12.9 25% increase in sales of basic markers, up to PLN 7.1 million 20% increase in sales of special markers, up to P
Slide 20: Cardiotracer
SYNEKTIK SA Cardiotracer Q3 FY 2024 Financial results | Investor presentation 20
Slide 21: Synektik S.A. spin-off plan adopted
Synektik S.A. spin-off plan adopted On July 23, 2025, the management boards of Synektik S.A. and Syn2bio S.A. (in organization) agreed on and adopted a plan to divide Synektik SA into two independent publicly listed entities: To Syn2bio SA (in organization), in exchange for shares of a new issue
Slide 22: Q&A Session
SYNEKTIK SA Q&A SESSION Q3 FY 2024 Financial results | Investor presentation 22
Slide 23: Thank you!
Cezary Kozanecki Thank you! President of the Management Board, CEO ckozanecki@synektik.com.pl Dariusz Korecki Vice-President of the Management Board, CFO dkorecki@synektik.com.pl